Reactions cutanees indesirables des traitements par anticorps monoclonaux.

Pierard, Claudine; Pierard, Gérald

Download

Article (Scientific journals)

Reactions cutanees indesirables des traitements par anticorps monoclonaux.

Pierard, Claudine; Pierard, Gérald

2009 • In Revue Médicale de Liège, 64 (5-6), p. 339-46

Peer reviewed

Permalink
https://hdl.handle.net/2268/12645

PubMed
19642471

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

REACTIONS...MONOCLONAUX.pdf

Publisher postprint (2.12 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Antibodies, Monoclonal/adverse effects; Drug Eruptions/etiology; Humans

Abstract :

[en] A number of adverse skin reactions can occur during some treatments using monoclonal antibodies. Some of the reactions are specifically linked to the pharmacological effect of the drug. Others are the expression of more common drug reactions. Their early recognition and their adequate management are important to consider in order to avoid a morbidity severely altering the quality of life and even the life prognosis.

Disciplines :

Dermatology

Author, co-author :

Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

Reactions cutanees indesirables des traitements par anticorps monoclonaux.

Alternative titles :

[en] Cutaneous adverse reactions to monoclonal antibody treatments

Publication date :

2009

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

5-6

Pages :

339-46

Peer reviewed :

Peer reviewed

Available on ORBi :

since 11 December 2009

Statistics

Number of views

343 (1 by ULiège)

Number of downloads

5345 (21 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Agero ALC, Dusza SW, Benvenuto-Andrade C, et al.- Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol, 2006, 55, 657-670. (Pubitemid 44436627)
Piérard-Franchimont C, Blaise G, Paquet P, et al.- Acné iatrogène paroxystique et les inhibiteurs du facteur de croissance épidermique (EGFR). Rev Med Liège, 2007, 62, 11-14.
Salama JK, Seiwert TY, Vokes EE.- Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol, 2008, 135, 148-153.
Bonner JA, Ang K.- More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med, 2007, 357, 1872-1873. (Pubitemid 350044823)
Harari PM, Allen GW, Bonner JA.- Biology of interactions : antiepidermal growth factor receptor agents. J Clin Oncol, 2007, 25, 4057-4065. (Pubitemid 47492950)
Marty M, Cognetti F, Maranincki D, et al.- Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human EGFR2 positive metastatic breast cancer administered as first line treatment. J Clin Oncol, 2005, 23, 4265-4274. (Pubitemid 46207001)
Cohen AD, Mermershtain W, Geffon DB, et al.- Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins. J Dermatol Treat, 2005, 16, 19-21. (Pubitemid 40283319)
Autier J, Mateus C, Wechsler J, et al.- Effets secondaires cutanés de sorafénib et du sunitinib. Ann Dermatol Venereol, 2008, 135, 148-153. (Pubitemid 351625321)
Lee HH, Song IH, Friedrich M, et al.- Cutaneous sideeffects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol, 2007, 156, 486-491. (Pubitemid 46253946)
Ramos-Casals M, Brito-Zerón P, Muñoz S, et al.- Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine, 2007, 86, 242-251. (Pubitemid 47067483)
Tutar E, Ekici F, Naçar N, et al.- Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatology, 2004, 43, 674-675. (Pubitemid 38628208)
Vergara G, Silvestre JF, Betlloch I, et al.- Cutaneous drug eruption to infliximab : report of 4 cases with an interface dermatitis pattern. Arch Derm, 2002, 138, 1258-1259. (Pubitemid 35025713)
Ettefagh L, Nedorost S, Mirmirani P.- Alopecia areata in a patient using infliximab : new insights into the role of tumor necrosis factor on human hair follicles. Arch Derm, 2004, 140, 1012. (Pubitemid 39062659)
Ranganathan P.- Infliximab-induced scleredema in a patient with rheumatoid arthritis. J Clin Rhem, 2005, 11, 319-322. (Pubitemid 44384023)
Gilaberte Y, Coscojuela C, Vázquez C, et al.- Perforating folliculitis associated with tumour necrosis factoralpha inhibitors administered for rheumatoid arthritis. Br J Dermatol, 2007, 156, 368-371. (Pubitemid 46095968)
Deng A, Harvey V, Sina B, et al.- Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Derm, 2006, 142, 198-202. (Pubitemid 43276531)
Bongartz T, Sutton AJ, Sweeting MJ, et al.- Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 2006, 295, 2275-2285. (Pubitemid 43736578)
Curtis JR, Patkar N, Xie A, et al.- Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum, 2007, 56, 1125-1133. (Pubitemid 46608637)
Lee HH, Song IH, Friedrich M, et al.- Cutaneous sideeffects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol, 2007, 156, 486-491. (Pubitemid 46253946)
Asano Y, Kano Y, shiohara T.- Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab. Acta Derm Venereol, 2008, 88, 183-184.
Bergstrom L, Yocum DE, Ampel NM, et al.- Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum, 2004, 50, 1959-1966. (Pubitemid 38725108)
Fabre S, Gibert C, Lechiche C, et al.- Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheum, 2005, 32, 242-243. (Pubitemid 41780660)
Dixon WG, Watson K, Lunt M, et al.- Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : results from the British Society for Rheumatology Biologics Register. Arth Rheum, 2006, 54, 2368-2376. (Pubitemid 44204996)
Smith KJ, Skelton HG.- Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. JAAD, 2001, 45, 953-956. (Pubitemid 33096643)
Esser AC, Abril A, Fayne S, Doyle JA.- Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. JAAD, 2004, 50, S75-S77. (Pubitemid 38580526)
Lebwohl M, Blum R, Berkowitz E, et al.- No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Derm, 2005, 141, 861-864. (Pubitemid 41058067)
Bovenschen HJ, Tjioe M, Vermaat H, et al.- Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Derm, 2006, 154, 880-884.
Tximberidou AM, Giles FJ, Duvic M, Kurzrock R.- Pilot study of etanercept in patients with relapsed cutaneous T cell lymphomas. J Am Acad Dermatol, 2004, 51, 200-204.
Passarini B, Infusino SD, Barbieri E, et al.- Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology, 2007, 215, 295-300. (Pubitemid 47519257)
Wollina U, Hansel G, Koch A, et al.- Tumor necrosis factor-(alpha) inhibitor-induced psoriasis or psoriasiform exanthemata : first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol, 2008, 9, 1-14.
Gellrich S, Muche JM, Wilks A, et al.- Systemic eight cycle anti CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation. Br J Dermatol, 2005, 153, 167-173. (Pubitemid 41044544)
Perez-Gala S, Delgado-Jimenez Y, Goirez R, et al.- Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma. Arch Dermatol, 2006, 142, 1516-1517. (Pubitemid 44790658)
Lowndes S, Darby A, Read G, Lister A.- Stevens Johnson syndrome after treatment with rituximab. Ann Oncol, 2002, 13, 1948-1950. (Pubitemid 36040785)
Fogary GB, Bayne M, Bedford P, et al.- Three cases of activation of cutaneous squamous cell carcinoma during treatment with prolonged administration of rituximab. Clin Oncol (R. Coll Radiol), 2006, 18, 155-156. (Pubitemid 43169149)
Puechal X, Rivereau P, Vinchon F.- Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med, 2008, 19, 364-366. (Pubitemid 351783388)